Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new dr...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that...
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. (...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission...
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the Company has entered ...
Cue Biopharma, a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, announced positive topli...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
Approximately 600 patients expected to be enrolled at clinical sites across the United States, Europe, China and South America Global Phase 3 program, R...
Rezubio announced that it has successfully completed dosing of the first cohort in its Phase 1 clinical trial following clearances from the US FDA a...
CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achieved EXCiPACT™ GMP Certifica...
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the Phase Ib/IIa clinical results of its anti-S...
HUTCHMED (China) Limited (“HUTCHMED”) announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license ...
© 2026 Biopharma Boardroom. All Rights Reserved.
